A pilot study for the effect of infliximab on endothelial function in patients with psoriasis
- Conditions
- Psoriasis vulgaris, Psoriatic arthritis, Pustular psoriasis, Erythrodermic psoriasis
- Registration Number
- JPRN-UMIN000027208
- Lead Sponsor
- The University of Tokyo Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 25
Not provided
1. Patients who are treated with other biologics within 3 months 2. Patients treated with cyclosporine within 2 weeks 3. Patients with the past history of severe hypersensitivity or anaphylaxis against infliximab or drugs including murine proteins. 4. Patients with or suspected of having malignancy 5. Patients with serious infection, such as sepsis and positivity of Hepatitis B virus antigen 6. Patients with active or the past history of tuberculosis 7. Patients with active or the past history of demyelinating diseases 8. Patients with congestive heart failure 9. Patients with serious liver diseases (more than 300 IU of AST or ALT) 10. Patients with serious kidney diseases (serum creatinine >= 2.0mg/dl) 11. Patients under or suspected of pregnancy 12. Patients under breast feeding 13. Patients who are regarded to be inappropriate for this study by doctors
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method The percentage improvement in reactive hyperemia index measured by EndoPAT at 4 hours after the third infusion compared with the baseline
- Secondary Outcome Measures
Name Time Method